Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 390 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump April 4, 2019 Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical... May 5, 2021 Acing it: The ambitious early career researchers driving progress in cancer... January 21, 2022 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 Load more HOT NEWS Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with... Survivors of Childhood Cancer are at Excess Risk of Late Mortality... Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of...
